MAPK1 and cancer: In the context of Kras G12D‐driven pancreatic ductal carcinoma (PDAC), pharmacological inhibition of KRAS or its downstream effector MAPK1/ERK2 (mitogen‐activated protein kinase 1) further increases the autophagic flux, while enhancing the dependency of cancer cells to intact autophagy (Bryant et al, 2019; Kinsey et al, 2019).